PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:86
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    CANCERS, 2020, 12 (05)
  • [3] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [4] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [5] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Baquerizo, Angeles
    Vavinskaya, Vera
    Rojas, Angela
    Mhoyan, Anna
    Romero-Gomez, Manuel
    Sher, Linda
    Madani, Bahar
    Fisher, Jonathan
    Schaffer, Randolph
    Frenette, Catherine T.
    Marsh, Christopher
    HEPATOLOGY, 2019, 70 : 206A - 206A
  • [6] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [7] β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
    Wang, Mengjie
    Bai, Yu
    Pei, Jiaxin
    Li, Dongqing
    Pu, Xiaolin
    Zhu, Wenyu
    Xia, Lei
    Qi, Chunjian
    Jiang, Hua
    Ning, Yongling
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] PD-L1/PD-1 In Hepatocellular Carcinoma: An Institutional Review
    Poveda, Julio
    Duarte, Melissa
    Jones, Patricia Denise
    Chowdhury, Aneesa
    Brown, Kevin
    Garcia-Buitrago, Monica
    LABORATORY INVESTIGATION, 2019, 99
  • [9] PD-L1/PD-1 In Hepatocellular Carcinoma: An Institutional Review
    Poveda, Julio
    Duarte, Melissa
    Jones, Patricia Denise
    Chowdhury, Aneesa
    Brown, Kevin
    Garcia-Buitrago, Monica
    MODERN PATHOLOGY, 2019, 32
  • [10] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735